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Abstract
Background: Mycobacterium ulcerans disease (Buruli ulcer) is a neglected tropical disease common amongst children in
rural West Africa. Animal experiments have shown that tissue destruction is caused by a toxin called mycolactone.
Methodology/Principal Findings: A molecule was identified among acetone-soluble lipid extracts from M. ulcerans (Mu)-
infected human lesions with chemical and biological properties of mycolactone A/B. On thin layer chromatography this
molecule had a retention factor value of 0.23, MS analyses showed it had an m/z of 765.6 [M+Na+] and on MS:MS
fragmented to produce the core lactone ring with m/z of 429.4 and the polyketide side chain of mycolactone A/B with m/z
of 359.2. Acetone-soluble lipids from lesions demonstrated significant cytotoxic, pro-apoptotic and anti-inflammatory
activities on cultured fibroblast and macrophage cell lines. Mycolactone A/B was detected in all of 10 tissue samples from
patients with ulcerative and pre-ulcerative Mu disease.
Conclusions/Significance: Mycolactone can be detected in human tissue infected with Mu. This could have important
implications for successful management of Mu infection by antibiotic treatment but further studies are needed to measure
its concentration.
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Introduction
Mycobacterium ulcerans (Mu) disease (Buruli ulcer) is common in
humid rural tropical areas mainly in West Africa and predomi-
nantly affects children between 5 and 15 years of age [1]. The
classic lesion is a painless nodule which breaks down centrally to
form an ulcer with undermined edges. Histology shows clumps of
acid fast bacilli in areas of subcutaneous fatty necrosis with acute
and chronic inflammation remote from the necrotic areas.
Granulomas are found in later lesions [2]. This histopathology
led to the suggestion that Mu causes disease by secretion of a toxin
which can destroy human tissue and inhibit the development of
local inflammation [3]. Subsequently it was found that M. ulcerans
culture filtrate could produce similar lesions after injection into
guinea pig skin [4].
Initial attempts to isolate this substance were frustrated by low
yields from cultures until the late 1990s when a toxin called
mycolactone was partly purified and its chemical structure defined
[5]. Subsequently mycolactone has been characterised as a 743 Da
molecule consisting of a 12-membered ring macrolide with two
polyketide derived side chains (figure 1) synthesised by giant
polyketide synthases and polyketide modifying enzymes whose
genes are carried on two identical copies of a 174 kb plasmid
known as pMUM001 [6]. Mycolactone causes a cytopathic effect
on mouse fibroblast L929 cells characterised by cytoskeletal
rearrangement with rounding up and subsequent detachment
from tissue culture plates within 48 hours. The toxin causes cell
cycle arrest in the G0/G1 phase within 48 hours, proceeding to
cell death by apoptosis after 72 hours [7].
Various elegant in-vitro and in-vivo studies in mice and guinea pigs
have demonstrated that this polyketide toxin is central to the
pathogenesis of M. ulcerans disease. George et al demonstrated that
injection of 100 mg of mycolactone was sufficient to cause
characteristic ulcers in guinea pig skin [7] and that histopathological
changes could be detected with 10 mg. Although direct inoculation
of mycolactone intradermally into guinea pigs caused necrotic
lesions similar to those produced by the injection of live organisms,
an isogenic toxin-negative mutant M. ulcerans was phagocytosed by
macrophages and stimulated a typical mycobacterial inflammatory
response, including granuloma formation. Chemical complemen-
tation of this mutant with mycolactone restored virulence [8].
Histologically these lesions showed significant apoptotic cell death
[9], a feature which has been observed in human lesions [10].
Mycolactone has also been associated with vacuolar nerve tissue
damage in mice and this observation may account for the
painlessness of Buruli ulcer lesions [11].
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The classic histological feature of human Buruli ulcer lesions is
subcutaneous fatty necrosis with clumps of AFB in the absence of
inflammatory cells. The necrosis is explained by cytotoxic
properties of mycolactone but the paucity of inflammatory cells
despite extensive skin damage may be due to its immunosuppres-
sive properties. Mycolactone has been shown to inhibit the
responses of macrophages and activated T-cells in-vitro [12], to
inhibit phagocytosis by murine macrophages [13], to induce lysis
of cultured macrophages after a transient intracellular growth [14]
as well as to impair the production of TNF-alpha by these cells
[15] and to inhibit induction of chemokine secretion by dendritic
cells [16]. Therefore high concentrations of mycolactone in
necrotic foci may kill cells by apoptosis or necrosis but its diffusion
away from the centre of lesions where infiltrates of neutrophils and
macrophages are found may serve to modulate the release of
chemokines and cytokines by these inflammatory cells without
killing them.
Despite the obvious role of mycolactone in virulence, the fact
that the molecule is a lipid rather than a protein has made it
difficult to study in vivo. The molecule has not been detected in vivo
in human Buruli ulcer lesions making it impossible to answer
questions regarding its distribution and stability. Although it has
been assumed that mycolactone is present in all stages of infection,
there has been no evidence to support this speculation. The aim of
the present studies was therefore to identify mycolactone among
lipids extracted from human skin infected with Mu.
Materials and Methods
Ten patients with a clinical diagnosis of M. ulcerans disease were
recruited at Tepa Government Hospital in the Ahafo Ano north
district in the Ashanti Region of Ghana. After the patients had
given informed consent, two 4 mm punch biopsies were obtained
from the centre of non-ulcerated lesions or from the edge of the
viable skin around ulcers. One biopsy was used to establish the
diagnosis of Mu disease using microscopy, culture and PCR for the
repeat sequence IS2404 of Mu as described elsewhere [17]. To
detect Mu, homogenised tissue was stained by the Ziehl-Neelsen
technique and 1 ml was decontaminated by the modified Petroff
method for 10 minutes and inoculated onto Lo¨wenstein-Jensen
slopes. Cultures were incubated at 31uC and examined weekly for
6 months before they were discarded. DNA extraction was
performed by the guanidinium thiocyanate diatoms technique [17]
and PCR was performed targeting the 1S2404 insertion sequence
as described elsewhere [17]. The other biopsy specimen was snap
frozen in liquid nitrogen and stored at 270uC for lipid analysis.
Extraction of lipids from human skin
Lipids were extracted from Buruli ulcer lesions using chlor-
oform:methanol 2:1 (vol/vol) followed by a Folch extraction with
0.2 volumes water. Briefly, the punch biopsy was weighed and
placed in a 1.5 ml green top matrix tube containing 500 ml of
diatoms (Q-bio) and homogenised in extractant solution for 45
seconds at a power of 6.5 in a Fast Prep Ribolyser.The
homogenate was transferred into a microfuge tube and allowed
to stand for 30 minutes. After centrifugation at 10,000 g for 2
minutesthe organic phase was harvested. The organic phase was
dried in a roto-evaporator and re-suspended in ice-cold acetone
for 1 hour to precipitate phospholipids. Acetone soluble lipids
(ASL) were harvested for mycolactone detection by thin layer
chromatography, mass spectrometry and cytopathicity assays. For
cytopathicity assays, half of the total volume of lipid extracts were
dried under nitrogen gas and shipped to the University of
Tennessee, U.S. where analyses were performed. The other half of
tissue lipid extracts were analysed for cytotoxicity using an MTT
assay, fluorescent microscopy for characterisation of cell death and
TNF-alpha induction assays at St. George’s, University of London,
U.K.
To optimise the extraction technique and determine the limit of
detection, 100 mg, 10 mg, 1 mg and 0.1 mg quantities of myco-
lactones were used to spike approximately 100 mg of healthy skin
tissue. Healthy human skin was obtained during excision of a
lipoma with patient permission. Mycolactone was extracted from
spiked skin samples as described above.
Preparation of mycolactone A/B from bacterial extracts
Mycolactone was prepared from M. ulcerans extracts as
previously described [5]. Briefly, M. ulcerans cultures were grown
in Middlebrook M7H9 broth with OADC supplement until early
stationary phase. Bacteria were harvested by centrifugation and
mycolactone was extracted from dried bacterial pellets using
chloroform:methanol 2:1 followed by Folch extraction with 0.2
volumes water. Acetone-soluble lipids (ASL) highly enriched for
mycolactone were obtained by drying lipids under nitrogen and
enriched for mycolactone by precipitating phospholipids with ice
cold acetone. Purified mycolactone was obtained from ASL by
Figure 1. Chemical structure of mycolactone A/B showing the
lactone core ring and polyketide side chains.
doi:10.1371/journal.pntd.0000577.g001
Author Summary
Skin infection with bacteria called Mycobacterium ulcerans
causes Buruli ulcer, a disease common in West Africa and
mainly affecting children. M. ulcerans is the only myco-
bacterium to cause disease by production of a toxin. This
lipid molecule called mycolactone diffuses from the site of
infection, killing surrounding cells and, at low concentra-
tion, suppressing the immune response. The aim of this
study was to show that mycolactone can be detected
among lipids extracted from human M. ulcerans lesions in
order to study its role in the pathogenesis of M. ulcerans
disease. Lipids were extracted from skin biopsies and
tested for the presence of mycolactone using thin layer
chromatography and mass spectrometry. The extracts
were shown to kill cultured cells in a cytotoxicity assay.
Mycolactone was detected in both pre-ulcerative and
ulcerative forms of the disease and also in lesions during
antibiotic treatment but with reduced bioactivity, sug-
gesting a lower concentration compared to untreated
lesions. These findings indicate that there is mycolactone
in affected skin at all stages of M. ulcerans disease and it
could be used as a biomarker for monitoring the clinical
response to antibiotic treatment.
Mycolactone in M. ulcerans-Infected Human Tissue
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centripetal chromatography using a Harrison chromototron (Palo
Alto, CA). Samples were assessed by mass spectroscopic analysis to
validate purity.
Thin layer chromatography
Purified mycolactone A/B was applied to a silica thin layer
chromatography (TLC) plate and analysed using chloroform-
methanol-water (90:10:1 vol/vol/vol) as a solvent system. Lipid
bands were visualised under UV light and by oxidative charring
with ceric sulphate-ammonium molybdate in 2M sulphuric acid.
Serial dilutions of purified mycolactone from 125 mg/ml to
1.4 mg/ml were spotted onto TLC plates to determine the
detection limit for the system.
20 ml of acetone soluble lipids from spiked skin samples,
negative controls and infected human tissues were analysed by
TLC to detect the presence of mycolactone bands.
Electron spray ionisation mass spectrometry (MS)
Acetone soluble lipids were dissolved in ethanol and directly
perfused into an electrospray ionization source on a Bruker
Esquire 2000 mass spectrometer using a Cole Palmer 74900 series
syringe pump. The electrospray MS conditions were initially
optimized to a mycolactone standard before applying them to the
lipid extracts. The electrospray MS conditions were: infusion rate
1,000 ml/h; nebulizer pressure 30 lb/in2; dry gas flow 10 l/min;
dry temperature 320uC; capillary voltage 24,000 V; end plate
offset 2500 V. Detection of mycolactone was determined by the
presence or absence of ions characteristic of mycolactone: the
more abundant sodium adduct [M+Na]+ (m/z 765.5); the
protonated molecular ion [M+H]+ (m/z 743.5), and the
dehydrated protonated molecular ion [M+H - H2O]+ (m/z
725.5). ESI-MS/MS analyses were performed on the m/z 765.5
component for the characteristic fragmentation pattern compris-
ing ions corresponding to the core lactone and the polyketide side
chain respectively.
Cytopathic effect assays
L929 murine fibroblasts were maintained in Dulbecco’s
modified Eagle’s medium with 5% foetal calf serum in tissue
culture flasks and incubated in 5% carbon dioxide at 37uC. ASL
samples which had been dried under nitrogen were dissolved in
50 ml absolute ethanol. 2.5 ml (5%) or 5 ml (10%) of the resultant
solution was added to cells in a 96-well tissue culture plate to
determine cytopathic effect (CPE). CPE was defined as the
minimal concentration of ASL per millilitre necessary to produce
90% cell rounding in 24 h and loss of the monolayer by 48 h.
Cytotoxicity of ASL from infected human tissues was further
assessed by the ability of mycolactones to inhibit mitochondrial
succinate dehydrogenases of human embryonic lung fibroblasts
(HELF) from reducing dimethylthiazolyl diphenyl tetrazolium
bromide (MTT) dye to form purple formazan crystals. Induction
of cell death was assessed by staining these cells with a dye mix of
ethidium bromide and acridine orange after treatment of HELF
cells with mycolactones positive controls, acetone soluble lipids
from infected patient samples and negative controls comprising
ASL a lipoma lesion, ethanol and untreated wells.
Briefly HELF cells (kindly donated by Dr. Kay Capaldi) were
maintained in Dulbecco’s modified Eagle’s medium supplemented
with 10% foetal calf serum and 2 mM L-glutamine in the presence
of penicillin and streptomycin 100 mU/ml and 100 mg/ml
respectively and incubated in 5% carbon dioxide at 37uC. For
cytotoxicity assays proliferating HELF cells were seeded at a
density of 105/well in microtitration plates overnight. ASL from
lesions, positive controls and negative controls were dissolved in
100 ml of absolute ethanol of which 5 ml was used to treat HELF
cells in quadruplicates. After 48 h incubation, 20 ml of 5 mg/ml of
MTT (Sigma) was added to each well and incubated for a further
4 h for purple coloured formazan crystals to develop following
which 100 ml of detergent solution of isopropanol: HCl (2N) in a
ratio of 49:1 was used to dissolve formazan crystals for
spectrophotometric quantification in multiplate well reader at
570–690 nm.
To characterise the pattern of cell death caused by mycolac-
tones in patient samples HELF cells were stained with 8 ml of a
combination of 100 mg/ml of ethidium bromide (Sigma) and
100 mg/ml of acridine orange (Sigma) (EB/AO) dye mix in
microtitration plates as previously described [18]. Cells were
observed with a DM1 6000B Leica fluorescent microscope and
images taken at x10 magnification.
To confirm the immunosuppressive properties of mycolactones
extracted from human lesion we measured release of TNF-a by
J774 macrophages pre-treated with ASL from patient lesions after
stimulation with lipopolysaccharide (LPS). Briefly, J774 macro-
phages (kindly donated by Dr. Rajko Reljic) were maintained in
Dulbecco’s modified Eagle’s medium supplemented with 10%
foetal calf serum and 2 mM L-glutamine in tissue flasks and
incubated in 5% carbon dioxide at 37uC. Proliferating macro-
phages were seeded at a density of 105 in 96-well microtitration
plates and allowed to adhere to culture plates over 4 h. Cells were
exposed to 5 ml of ASL from lesions or to purified mycolactones as
a positive control for 6 h and stimulated with 0.5 mg/ml of LPS
(Sigma) with a 16 h incubation in 5% CO2 at 37uC. Samples were
analysed in quadruplicates and experiments were repeated twice.
Supernates were harvested and TNF-a quantities assayed in
duplicate with a Quantikine ELISA kit (R & D Systems) according
to the manufacturer’s protocol. The limit of detection of TNF-a
was 23.4 pg/ml. Viability of macrophages after cytokine induction
assays was assessed with the MTT assay previously described.
Statistical analysis
Student’s t-test was used to test for significance by comparing
cytotoxicity and TNF-alpha release by cultured cell lines treated
with lipid extracts from patient samples and negative controls with
a p,0.01 considered significant. The Mann-Whitney U test was
used to compare TNF-alpha release by macrophages treated with
lipid extracts from untreated and antibiotic treated lesions with
p,0.05 considered statistically significant.
Ethical review
The study protocol was approved by the ethics review
committees at the School of Medical Sciences, Kwame Nkrumah
University of Science and Technology, Kumasi, Ghana, and St.
George’s Hospital in London, United Kingdom. Informed consent
was obtained orally since the patients were illiterate and consent
was given by thumb print as approved by the ethics committees.
Results
Patient characteristics
Table 1 shows the characteristics of the 10 patients with PCR-
confirmed M. ulcerans infection whose mean age was 17 years.
There were 5 nodules, 4 oedematous lesions, 3 of which had
ulcerated, and 1 ulcer without oedema. Five patients had received
antibiotic therapy consisting of intramuscular streptomycin
15 mg/kg daily and oral rifampicin 10 mg/kg daily, 4 for 4
weeks and one for 6 weeks. Four out of 5 untreated lesions were
culture positive and 3 out of 5 lesions were also culture positive
after 4 or 6 weeks of treatment as shown in Table 1.
Mycolactone in M. ulcerans-Infected Human Tissue
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Table 1. Patient characteristics, diagnostic data and treatment status.
Code Age(years) Sex Lesion Type A.F.B. Culture on L.J. P.C.R. Treatment Status*
7 10 F oedema with ulcer negative positive positive untreated
8 18 F nodule negative positive positive 4 weeks antibiotics
9 16 M oedema with ulcer negative positive positive untreated
10 15 M oedema with ulcer +++ negative positive untreated
11 9 F nodule negative positive positive untreated
12 32 M oedema negative negative positive 6 weeks antibiotics
13 16 F nodule negative negative positive 4 weeks antibiotics
14 11 M nodule negative positive positive untreated
15 25 F nodule ++ positive positive 4 weeks antibiotics
16 18 M ulcer +++ positive positive 4 weeks antibiotics
*Antibiotic treatment was with streptomycin injection15 mg/kg and oral rifampicin 10 mg/kg daily.
doi:10.1371/journal.pntd.0000577.t001
Figure 2. Detection of mycolactone A/B by thin layer chromatography. A. 20 ml of two-fold serial dilutions of mycolactone A/B at
concentrations from 125 to 1 mg/ml were spotted and examined under UV-light and by oxidative charring. The detection limit on TLC was at a
concentration of 2–8 mg/ml (8 mg corresponding to 160 ng of mycolactone A/B). B. Each track represents one sample. M is purified mycolactone A/B;
tracks 1 and 2 are positive controls with100 mg of purified mycolactone; tracks 3 and 4 are samples extracted from human skin spiked with 100 mg of
purified mycolactone; tracks 5 and 6 are negative controls from healthy human skin; tracks 7 to 16 are extracts from infected human skin samples.
Mycolactone A/B was the predominant UV-active band with an Rf of 0.23 in positive controls and in ASLs from infected human skin. There were
perceptible signals from patients 7, 8, 11, 14 and 15 whereas samples from 9, 10, 12, 13 and 16 were below the detection limit.
doi:10.1371/journal.pntd.0000577.g002
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Figure 3. Detection of mycolactone by mass spectrometry. A. MS analysis of ASL from Mu infected human skin showing a molecule with m/z
765.5 which represents the sodium adduct of mycolactone A/B [M+Na+]. B. MS-MS analysis of this ion produced the core lactone ring of mycolactone
with m/z 429.4 and the polyketide side chain of mycolactone A/B with m/z 359.2.
doi:10.1371/journal.pntd.0000577.g003
Mycolactone in M. ulcerans-Infected Human Tissue
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Detection of mycolactone A/B in human skin lesions
Using TLC, purified mycolactone A/B yielded a major UV
active band at a retention factor (Rf) value of 0.23 and two minor
bands. The detection limit of mycolactone on TLC was 2–8 mg/
ml as shown in figure 2A. Figure 2B shows that acetone soluble
lipids from 5 lesions had detectable bands at Rf 0.23 which were
UV active and corresponded to the purified mycolactone A/B
ladder M. These bands were from 1 untreated oedematous BU
lesion with ulceration, 2 untreated nodules and 2 antibiotic treated
nodules. All those with detectable mycolactone signals on TLC
were also culture positive. However 5 other lesions did not show
perceptible bands on TLC plates. Three of these patients were on
antibiotics while the other 2 patients had untreated oedematous
lesions.
Mass spectral analysis of acetone soluble lipids from infected
human lesions under microspray conditions revealed the presence
of an ion with mass to charge ratio (m/z) of 765.5 [M+Na+] which
corresponded to that of mycolactone A/B (Figure 3A). Fragmen-
tation of this ion yielded ions with m/z 429.3 corresponding to the
conserved core lactone ring present in all mycolactone congeners
and with m/z of 359.2 corresponding to the polyketide side chain
of mycolactone A/B. In addition ions were also observed at m/z
341.2, 565.3, 579.4, 659.4, 677.4, 707.4, 721.3, 747.4 and 766.4
(Figure 3B).
Mycolactone A/B was detected in acetone soluble lipids from
all 10 patients by mass spectrometry. Using mycolactone 100 mg,
10 mg, 1 mg and 0.1 mg to spike approximately 100 mg of healthy
skin tissue, mycolactone signals could be detected on MS
from those spiked with 100 mg and 10 mg but not at lower
concentrations.
Cytopathicity assays of human acetone soluble lipids
Mycolactone exhibits a characteristic cytotoxic phenotype
which includes cell rounding at 10 hours, cell cycle arrest at
36 hours and apoptotic cell death at 72 hours. We studied the
effects of ASL on L929 murine fibroblasts without purifying
mycolactone. This was justified since previous work has shown
that the cytotoxicity of lipids obtained by chloroform:methanol 2:1
extraction is entirely due to the presence of mycolactone [7]. The
classic cytotoxic phenotype of mycolactones was observed within
48 h upon treatment of murine fibroblasts with 5% ASL from
infected Mu lesions. However, using 10% ASL, a high
mycolactone concentration phenotype characterised by osmotic
swelling of cells with eccentric nuclei was observed at 24 hours as
previously described by Adusumilli et al [8] in all 10 patient
samples analysed (data not shown).
In MTT based cytotoxicity assays, ASL from Mu infected
lesions significantly inhibited mitochondrial succinate dehydroge-
nases of human embryonic lung fibroblasts (HELF) compared with
ASL from uninfected human skin as shown in Figure 4. ASL from
patient extracts also caused significant apoptotic cell death
comparable to 5 mg/ml of purified mycolactone after treatment
of HELF for 48 h (Figure 5). No qualitative differences were
observed in the physico-chemical properties, cytopathicity or pro-
apoptotic activities of lipid extracts from the different forms of Mu
infected lesions and there was no significant decline in percentage
cytotoxicity between 5 untreated and 5 antibiotic treated lesions
(Figure 4).
Inhibition of induction of TNF-a release by J774
macrophages
Mycolactone is known to potently inhibit the release of
cytokines at nanomolar, non-cytotoxic concentrations [16].
Figure 6 shows that ASL from infected human lesions significantly
inhibited TNF-a release by murine macrophages compared with
negative controls. There was no significant macrophage cytotox-
icity despite the profound inhibition of cytokine release. Although
there were no apparent differences in the degree of inhibition of
TNF-a by lipid extracts from the different Buruli lesion types,
significant recovery was observed in the release of TNF-a by
macrophages treated with lipid extracts from antibiotic treated
human lesions compared to untreated lesions (Figure 7) which may
indicate a decline in tissue levels of mycolactone during antibiotic
treatment.
Discussion
Our primary objective in this study was to isolate myco-
lactone from infected human lesions. We have extracted lipids
from infected human tissue using organic solvents and
identified mycolactone A/B by its recognised physical proper-
ties on chromatography and mass spectrometry and by its
biological activities such as cytotoxicity and immunosuppres-
sion. Our findings are the first definitive proof of the molecule’s
presence in infected human tissue and provide a foundation for
further studies on the kinetics of mycolactone-mediated
virulence.
Using ESI-MS, mycolactone A/B was detected in all 10 patient
samples as an ion with an m/z of 765.5 [M+Na]+ and confirmed
by its MSMS spectrum, the conserved core lactone ring and fatty
acid side chain producing characteristic ions at m/z 429.3 and
Figure 4. Cytotoxicity of ASL from human Mu lesions on
human embryonic lung fibroblasts. Cytotoxicity after 48 h culture
was assessed using an MTT assay. Negative control 1 is untreated cells,
negative control 2 is ASL from uninfected skin. Positive control was
purified mycolactone at a concentration of 5 mg/ml. Significant
cytotoxicity was observed with all patient samples with ***p,0.001
compared to negative control 1. The apparent difference in percentage
cytotoxicity between 5 untreated and 5 antibiotic treated lesions was
not statistically significant. HELF cells were treated in quadruplicates
and cytotoxicity determined in at least 2 independent experiments.
Data are shown as a percentage of untreated cells (negative control 1).
Error bars are 6SEM of duplicate assays.
doi:10.1371/journal.pntd.0000577.g004
Mycolactone in M. ulcerans-Infected Human Tissue
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359.2 respectively following fission of the ester bond with
additional ions observed identical to those previously reported
and identified in the MSMS spectrum of mycolactone A/B
[19,20].
Acetone soluble lipids from Mu infected lesions but not those
from negative control human skin showed the typical phenotypic
cytopathicity in cultured fibroblasts that is associated with
mycolactone. Cytotoxicity was assessed by the ability of ASL
from infected tissue to cause cytoskeletal re-arrangement,
rounding up of cells and detachment from culture plates as well
as inhibition of mitochondrial dehydrogenases. Furthermore
TNF-a induction by LPS was significantly impaired by lipid
extracts from infected human lesions but not by negative controls
(Figure 6). These findings confirm that mycolactone in these
clinical samples was biologically active both in its ability to cause
cell death and to modulate immune responses. The data from
these experiments provide the first direct evidence for the
presence of mycolactone in Mu infected human skin tissue.
Our observation that lipid extracts from human lesions induced
cell death by both necrosis and apoptosis implicates mycolactone
as the cause of the extensive tissue damage observed in humans
with Mu disease.
The detection of mycolactone A/B in three common clinical
forms of Mu lesions encountered in West Africa, namely
nodular, oedematous and ulcerative, in this study re-emphasises
its pivotal role in the pathogenesis of Mu disease. It is noteworthy
that the molecule was detected throughout the course of disease
from early nodular lesions to late ulcers. We also detected the
molecule in lesions during the course of curative antibiotic
therapy. Obiang et al in their landmark study reported that there
was no correlation between mycolactone profiles of bacterial
isolates from different patients and lesion type or severity [21].
These observations were not addressed in the present study but
our findings open up the possibility that mycolactone concen-
tration and type can be related to clinical presentation in future
studies.
Mycolactone was not detected by TLC in two specimens that
were AFB positive, one of which was also culture positive. This
may be because the organisms were producing only small amounts
of mycolactone, below the detection limit for TLC, or because the
biopsies were taken from adjacent but different sites.
Figure 2B shows bands at rf 0.78 in most of the human samples
but not in 9 and 10, and only weakly in 8. There was some
variation in the weight and lipid content of specimens which
might account for the different strength of non-mycolactone
bands in human samples. Sample 8 showed a clear mycolactone
band at rf 0.23 but only a very weak band at rf 0.78 suggesting
that this sample contained a high concentration of mycolactone
relative to the total lipid content. The purified mycolactone
showed a band at rf 0.85 (Figure 2B) suggesting that it still
contained some impurities but this does not affect the validity of
the results.
The observation that LPS stimulated TNF-a release from
murine macrophages was inhibited significantly more by lipid
extracts from untreated lesions than by ASL from antibiotic
treated lesions suggests that tissue mycolactone concentrations
declined during antibiotic therapy. However the sample size
was small and further prospective studies using quantitative
mycolactone assays are needed to investigate the pharmacoki-
netics of tissue mycolactone and to relate them to clinical
Figure 5. Cytotoxicity of mycolactone on HELF cells. A and B show the effect of ASL from Mu infected skin on HELF cells after 48 h with
detachment of cells from culture plate, numerous apoptotic cells (orange nuclei stained with acridine orange) and few live spindle shaped cells
(green nuclei with ethidium bromide). A and B represent ASL from a nodular lesion and an ulcerative lesion respectively. C shows the effect of
purified mycolactone at a concentration of 5 mg/ml and D is a negative control demonstrating the effect of ASL from uninfected human skin. Pictures
taken at x10 with a DM1 6000B Leica fluorescent microscope.
doi:10.1371/journal.pntd.0000577.g005
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responses to antibiotic therapy and the recovery of systemic
gamma interferon secretory responses we have observed [22].
The recent demonstration that mycolactone can be detected in
circulating murine mononuclear cells [23] may prove to be
pivotal in answering questions about the dynamics of the local
and systemic immune response to Mu during antibiotic
therapy.
In conclusion we have demonstrated for the first time the
presence of mycolactone A/B in Mu infected human tissue. Given
the central role played by mycolactone in the immunopathogen-
esis of Mu disease, it may be a useful marker for diagnosis and for
assessment of the response to antibiotic therapy. Ultimately it may
be possible to design molecules which can inhibit its synthesis or
block its actions for the purpose of treatment.
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Figure 6. The effect of acetone soluble lipids from human Mu lesions on TNF-a release by J774 macrophages. J774 macrophages were
stimulated with 0.5 mg/ml of LPS. Negative control 1 is untreated J774 macrophages, negative control 2 is J774 treated with ASL from uninfected skin.
Positive control refers to purified mycolactone at a concentration of 500 ng/ml and patient samples refers to all 10 patient lesions. ASL from infected
lesions significantly inhibited TNF-a release compared to both negative controls with ***p,0.001. Error bars are 6SEM of duplicate assays. Although
TNF-a release by J774 macrophages was significantly inhibited by purified mycolactone and lipid extracts from patient lesions, this occurred without
significant cytotoxicity.
doi:10.1371/journal.pntd.0000577.g006
Figure 7. Comparison of TNF-a release by J774 macrophages
treated with lipid extracts from 5 untreated and 5 antibiotic
treated Mu infected human lesions. TNF-a was inhibited signif-
icantly more by lipid extracts from untreated lesions compared to
antibiotic treated lesions. ***p,0.05 compared to untreated lesions.
Lipid extracts from all lesions had detectable mycolactone signal on
mass spectroscopic analysis.
doi:10.1371/journal.pntd.0000577.g007
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